3-(氯甲基)哒嗪盐酸盐 | 27349-66-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-(氯甲基)哒嗪盐酸盐
• 中文别名: 3-(氯甲基)哒嗪
• 英文名称: 3-(chloromethyl)pyridazine hydrochloride
• 英文别名: 3-(chloromethyl)pyridazine;hydrochloride
• CAS: 27349-66-2
• 化学式: C₅H₅ClN₂*ClH
• 分子量: 165.022
• InChiKey: LPKSYVXQAWQCSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.64
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H314
• 储存条件：
  存储条件：2-8°C，并需保存在惰性气体中。

反应信息

• 作为反应物：
  描述：

  二甲基吡啶胺 、 3-(氯甲基)哒嗪盐酸盐 在 四丁基溴化铵 、 sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 15.0h， 以68%的产率得到1-(pyridazin-3-yl)-N,N′-bis(pyridin-2-ylmethyl)methanamine
  参考文献：
  名称：

  Incorporation of Hydrogen‐Bonding Functionalities into the Second Coordination Sphere of Iron‐Based Water‐Oxidation Catalysts

  摘要：

  AbstractEnergy storage and conversion schemes based on environmentally benign chemical fuels will require the discovery of faster, cheaper, and more robust catalysts for the oxygen‐evolution reaction (OER). Although the incorporation of pendant bases into molecular catalysts for hydrogen production and utilization has led to enhanced turnover frequencies, the analogous incorporation of pendant bases into molecular catalysts for water oxidation has received little attention. Herein, the syntheses, structures, and catalytic activities of new iron complexes with pendant bases are reported. Of these new complexes, [Fe(L1)]2+ {L1 = N,N′‐dimethyl‐N,N′‐bis(pyridazin‐3‐ylmethyl)ethane‐1,2‐diamine} is the most active catalyst. Initial turnover frequencies of 141 and 24 h–1 were measured by using ceric ammonium nitrate at pH 0.7 and sodium periodate at pH 4.7, respectively. These results suggest that the incorporation of pendant bases into molecular catalysts for water oxidation might be an effective strategy that can be considered in the development of new catalysts for the OER, but will require the careful balance of many factors.

  DOI：

  10.1002/ejic.201201499
• 作为产物：
  描述：

  哒嗪-3-基甲醇 在 氯化亚砜 作用下， 反应 0.75h， 以100%的产率得到3-(氯甲基)哒嗪盐酸盐
  参考文献：
  名称：

  哒嗪/吡啶类含氮杂杂环铁（II）配合物的第二配位域中的协同相互作用有利于质子化

  摘要：

  新型哒嗪铁配合物，[ N，N，N'，N'-四（3-吡啶并甲基甲基）丙二胺]铁（II）（PF 6）2（1）和[ N，N'-双（2-吡啶并甲基） ）-N，N'-双（2-吡啶基甲基）丙二胺]铁（II）（PF 6）2（2）的合成，并将其对质子的反应性与类似的四吡啶配合物[ N，N，N'，N'-四（2-吡啶基甲基）丙二胺]铁（II）（PF 6）2（3）。溶液和固态结构已通过NMR和X射线晶体学研究证实。为1 - 3，配体结合在一六齿的方式给予类似八面体结构具有N 6配位环境。在整个系列中，越来越多的哒嗪仅对金属的光谱和电化学性质产生适度的影响。然而，它们对质子化的反应性截然不同。当2和3在强酸存在下分解时，1 由于第二球体的相互作用，它能够稳定地质子化。

  DOI：

  10.1002/ejic.201800533

文献信息

• [EN] SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018067786A1

  公开（公告）日：2018-04-12

  Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  1-取代的1H-咪唑[4,5-b]吡啶-2(3H)-酮作为NR2B受体配体。这类化合物可用于NR2B受体调节以及用于治疗由NR2B受体活性介导的疾病状态、疾病和病况的药物组合物和方法。
• Alkyl- or aryl-aminoalkoxy-benzene-sulfonyl indoles
  申请人：Sanofi

  公开号：US04994474A1

  公开（公告）日：1991-02-19

  The present invention relates to aminoalkoxyphenyl derivatives of formula: ##STR1## and its N-oxide and pharmaceutically acceptable salts, in which: B represents a--S--, --SO-- or --SO.sub.2 -- group, R.sub.1 and R.sub.2, which are identical or different, each denote hydrogen, a methyl or ethyl radial or a halogen atom, A denotes a straight-or branched-alkylene radical having from 2 to 5 carbon atoms or a 2-hydroxypropylene radial in which the hydroxy is optionally substituted by a lower alkyl radical, R.sub.3 denotes an alkkyl radical or a radical of formula: --Alk--Ar in which Alk denotes a single bond or a linear- or branched-alkylene radical having from 1 to 5 carbon atoms and Ar denotes a pyridyl, phenyl, 2,3-methylenedioxyphenyl or 3,4-methylenedioxyphenyl radical or a phenyl group substituted with one or more substituents, which may be identical or different, selected from halogen atoms, lower alkyl group or lower alkoxy groups, R.sub.11 denotes hydrogen or a lower alkyl, phenyl, diphenylmethyl, benzyl or halogenobenzyl radical, R.sub.4 denotes hydrogen or an alkyl radical, or R.sub.3 and R.sub.4 when taken together denote an alkylene or alkenylene radical having from 3 to 6 carbon atoms and optionally substituted with a phenyl radical or optionally interrupted by ##STR2## R represent hydrogen, an alkyl radical, a cycloalkyl radical, a benzyl radical or a phenyl radical optionally substituted with one or more substituents, which may be identical or different, selected from halogen atoms and from lower alkyl, lower alkoxy or nitro groups, are described. The compounds of the invention possess exceptional pharmacological properties, especially calcium transport inhibitory properties, as well as bradycardic, hypotensive and antiadrenergic properties.

  本发明涉及公式的氨基烷氧基苯基衍生物：##STR1##及其N-氧化物和药学上可接受的盐，其中：B代表a--S--，--SO--或--SO.sub.2--基团，R.sub.1和R.sub.2，它们相同或不同，每个代表氢，甲基或乙基基团或卤原子，A代表具有2至5个碳原子的直链或支链烷基基团或2-羟基丙烯基团，其中羟基可选择地被较低的烷基基团取代，R.sub.3代表烷基基团或公式的基团：--Alk--Ar，其中Alk代表单键或具有1至5个碳原子的直链或支链烷基基团，Ar代表吡啶基，苯基，2,3-亚甲二氧基苯基或3,4-亚甲二氧基苯基基团或一个苯基基团，其被一个或多个取代基取代，这些取代基可以相同或不同，选自卤原子，较低烷基基团或较低烷氧基团，R.sub.11代表氢或较低烷基，苯基，二苯甲基，苄基或卤代苄基基团，R.sub.4代表氢或烷基基团，或当一起取时，R.sub.3和R.sub.4代表具有3至6个碳原子并且可选择地被苯基取代或可选择地被##STR2##中断的烷基或烯基基团，R代表氢，烷基基团，环烷基基团，苄基基团或苯基基团，可选择地被一个或多个取代基取代，这些取代基可以相同或不同，选自卤原子和较低烷基，较低烷氧基或硝基基团。本发明的化合物具有出色的药理学性能，特别是钙转运抑制性能，以及心动过缓，降压和抗肾上腺素性能。
• Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
  申请人：Pfizer Inc

  公开号：US06723719B1

  公开（公告）日：2004-04-20

  Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; H is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction.

  化合物的公式（IA）和（IB）或其药理学或兽医学上可接受的盐，或者两者中的任一实体的药理学或兽医学上可接受的溶剂，其中R1是C1到C3烷基，取代为C3到C6环烷基，CONR5R6或N-连接的杂环基团；（CH2）nHet或（CH2）nAr；R2是C1到C6烷基；R3是C1到C6烷基，可选择地取代为C1到C4烷氧基；R4是SO2NR7R8；R5和R6分别独立选择自H和C1到C4烷基，可选择地取代为C1到C4烷氧基，或者与它们所连接的氮原子一起形成5-或6-成员杂环基团；R7和R8，与它们所连接的氮原子一起形成4-R10-哌嗪基团；R10是H或C1到C4烷基，可选择地取代为OH，C1到C4烷氧基或CONH2；H是可选择地取代的C-连接的5-或6-成员杂环基团；Ar是可选择地取代的苯基；n为0或1；是在治疗男性勃起功能障碍和女性性功能障碍等方面有用的有效且选择性的cGMP PDE5抑制剂。
• Aminoalkoxyphenyl derivatives, process of preparation and compositions
  申请人：Sanofi

  公开号：US05147878A1

  公开（公告）日：1992-09-15

  Aminoalkoxyphenyl derivatives useful in the treatment of certain pathological syndromes of the cardiovascular system of formula: ##STR1## in which: B represents a --S, --SO--, or --SO.sub.2 -- group, R.sub.1 and R.sub.2, which are identical or different, each denote hydrogen, a methyl or ethyl radical or a halogen such as chlorine, bromine or iodine, A denotes a straight- or branched-alkylene radical having from 2 to 5 carbon atoms or a 2-hydroxypropylene radical in which the hydroxy is optionally substituted by a lower alkyl radical, Ar represents a group ##STR2## R.sub.4 denotes hydrogen or an alkyl radical and Cy represents a cyclic group.

  氨基烷氧基苯基衍生物在治疗心血管系统某些病理综合征中有用，其化学式为：##STR1## 其中：B代表一个--S、--SO--或--SO.sub.2--基团，R.sub.1和R.sub.2，相同或不同，分别表示氢、甲基或乙基基团或氯、溴或碘等卤素，A表示具有2至5个碳原子的直链或支链烷基基团或2-羟基丙烯基基团，其中羟基可选择性地被较低的烷基基团取代，Ar代表一个基团##STR2## R.sub.4代表氢或烷基基团，Cy代表一个环状基团。
• Use of aminoalkoxyphenyl derivatives for reducing and/or controlling
  申请人：Sanofi

  公开号：US05017579A1

  公开（公告）日：1991-05-21

  The present invention is directed to the use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure and compositions suitable for this case.

  本发明涉及使用氨基烷氧基苯基衍生物来降低和/或控制过高的眼内压力，以及适用于此情况的组合物。